Be careful what you wish for: SGR and FFS will be models of the past; the success of the APM and MIPS will rely on compensation, collaboration and participation; and, to date, much remains to be done in the development of quality-based payment reform under MACRA.
New therapeutic targets provide hope for targeted treatments for rheumatoid diseases.
JAK inhibitors may be more effective than older biologic drugs in certain patients.
New data from studies of multiple drugs highlights Janssen’s commitment to rheumatic diseases.
Pfizer will highlight successes of Xeljanz at ACR/ARHP annual meeting.
Amgen will present findings from clinical studies of both branded and investigational drugs.
Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.
Research presented at the 25th European Academy of Dermatology and Venereology Congress focused on the effects of crisaborole topical ointment in treating atopic dermatitis.
Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.
New data for dupilumab presented at the 25th European Academy of Dermatology and Venereology Congress.
At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed effective techniques to boost HIV drug adherence.
The promise of sentinel lymph node biopsies for melanoma highlighted at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria.
Immune checkpoint inhibitors could improve malignant melanoma therapy, according to a study presented at the Congress of the European Academy of Dermatology and Venerology.
At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.
AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.
At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.
Clinical trial presented at the 25th Annual European Academy of Dermatology and Venereology Congress found a new topical allantoin cream can help treat epidermolysis bullosa.
Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, kicked off the European Academy of Dermatology and Venereology Congress highlighting the future of dermatology treatment.
Data presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress shows safety and efficacy of apremilast (Otezla) over three years.
Aleksandar L. Krunic, MD, PhD, discusses tumor removal in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.
Aleksandar L. Krunic, MD, PhD, discusses treatment strategies for rare tumor types in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.
Although it's difficult to determine exactly how many patients experience opioid-induced constipation, the large quantities of prescribed opioids in circulation create widespread potential for this bothersome adverse effect.
The opioid overdose death toll has been steadily increasing for more than a decade, making it a leading cause of accidental death in the United States.
Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacists can help prevent OIC.
Mary M. Bridgeman, PharmD, BCPS, CGP, discusses counseling points for OIC patients.
Jeffrey Gudin, MD, outlines the steps pharmacists should take to reduce opioid-induced constipation.
Mary M. Bridgeman, PharmD, BCPS, CGP, discusses the latest advancements in OIC treatment.
Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses potential adverse effects associated with naloxone.
Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacy-based OIC care differs from other settings.
Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system pharmacists can assess patients' risk for opioid overdose.
